Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF | V.TLT.WT

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Asco Gu abstract released

<< Previous

Bullboard Posts

Next >>

Comment by ScienceFirston Feb 13, 2023 8:46pm

327 Views

Post# 35284279

RE:Asco Gu abstract released

Apart data, which is phenomenal when compared to competition and that confirms my previous posts on potential upcoming efficacy %s around 65%+ @450-days as we add more and more optimized patients and will secure a FDA approval in due time, there are these others things that are very interesting in this poster:

1) Excellent Safety profile:

None of the SAEs were deemed to be directly related to the PDT.

2) Stats involved Harvard biostatistician:

Victor De Gruttola, - Research Professor of Biostatistics - Harvard T.H. Chan School of Public Health

3) Dr. Kamat (MD-Anderson and also our on our MSAB)

Ashish M. Kamat, MD - Scientific Advisory Board - Bladder Cancer Advocacy Network

Ashish M. Kamat | MD Anderson Cancer Center

Bladder Cancer: A Practical Guide - Ashish Kamat & Peter Black

What's Up with Bladder Cancer and BCG, with Dr. Ashish Kamat

4) We have the top 3 canadian urologists

- Dr. Kassouf (McGill CSS) ...

Has been for 10y (and still involved) Chairman of the Bladder Cancer Canada Scientific Advisory Board and BCAN

BCAN Emeritus Member | Wassim Kassouf, MD

Dr. Wassim Kassouf (MD, CM, FRCSC) - Bladder Cancer Canada

- Dr. Black (Univ. of B-C CSS)

Editorial Team: Peter Black - European Urology

Board Members - IBCN - Dr. Peter Black - Secretary

5) Dr. Donald L. Lamm (Arizona CSS)

Dr. Lamm is recognized as a BCG top reference.

Protocol for BCG + maintenance, Donald L. Lamm, MD

Dr. DL Lamm [https://www.bcgoncology.com] has been a pioneer in the field of immunotherapy (BCG) for bladder cancer since the early ‘80’s. After 28 years of academic practice, Dr. Lamm has opened a private practice limited to genito-urinary oncology:
Bladder Cancer, Genitourinary Oncology; BCG Oncology, P.C.
16620 N. 40th St. Suite E, Phoenix AZ 85032

6) Disclosures of authors:

https://coi.asco.org/Report/ViewAbstractCOI?id=396494

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects